Pure Global
NCT05807919

Evaluating the Efficacy of the Mediterranean Diet to the Low- Fermentable, Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAP) Diet in Treating Irritable Bowel Syndrome(IBS)

Evaluate and Compare the Clinical Efficacy of the Mediterranean Diet to the Low-FODMAP Diet in Treating Irritable Bowel Syndrome
University of Michigan·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Irritable Bowel Syndrome
Drug/Device/Intervention
Diet low in all FODMAP groups
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
University of Michigan
Location
Ann Arbor, United States of America
Timeline & enrollment
Phase
N/A
Start date
Apr 10, 2023
End date
Apr 01, 2024
Enrollment
20 participants
Primary outcome

Proportion of patients that are responders based on the abdominal pain intensity score for at least 2 of the 4 weeks

Summary

This study is being completed to determine if the Mediterranean (MD) and low FODMAP
 (fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols) diets are
 comparable in the effectiveness to treat Irritable Bowel Syndrome (IBS).
 
 The study team hypothesizes that:
 
 - The low FODMAP and Mediterranean groups will achieve a similar improvement in abdominal
 pain
 
 - Both groups will achieve similar improvements in bloating, overall IBS symptom severity,
 and adequate relief

ICD-10 classifications
Irritable bowel syndromeOther and unspecified irritable bowel syndromeIrritable bowel syndrome with mixed bowel habits [IBS-M]Irritable bowel syndrome with predominant constipation [IBS-C]Irritable bowel syndrome with predominant diarrhoea [IBS-D]
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05807919
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05807919 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Michigan and is currently Recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.